FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2061821116> ?p ?o ?g. }

• W2061821116 endingPage "S4" @default.
• W2061821116 startingPage "S3" @default.
• W2061821116 abstract "Since the introduction of autologous blood progenitor cell transplantation, (APCT) bone marrow suppression is no longer dose-limiting after high-dose therapy. We have developed a high-dose chemotherapy regimen ‘CTC’, that includes cyclophosphamide (6 g/m2), thiotepa (480 mg/m2) and carboplatin (1600 mg/m2) administered over four days. This regimen has been shown to be well-tolerated in over 80 (first) courses and multiple courses could be feasible. 28 patients received 2 courses of CTC, CTC-2 beginning on day 28 after the first APCT. One patient died of sepsis, one developed reversible veno-occlusive disease (VOD). Eleven patients received 3 subsequent courses of CTC. There were three toxic deaths: 1 × sepsis, 1 × VOD, 1 × hemolytic uremic syndrome (HUS). Two other patients developed reversible VOD, one had reversible HUS. While two closely spaced CTC courses are feasible, three subsequent courses are associated with frequent unacceptable organ toxicity. Preliminary data of a phase I/II study in advanced breast cancer suggest that three tightly spaced ‘tiny CTC’ courses—containing 2/3 of the doses of each of the agents in a standard CTC course—may be well tolerated and are not associated with excess organ toxicity. Since the introduction of autologous blood progenitor cell transplantation, (APCT) bone marrow suppression is no longer dose-limiting after high-dose therapy. We have developed a high-dose chemotherapy regimen ‘CTC’, that includes cyclophosphamide (6 g/m2), thiotepa (480 mg/m2) and carboplatin (1600 mg/m2) administered over four days. This regimen has been shown to be well-tolerated in over 80 (first) courses and multiple courses could be feasible. 28 patients received 2 courses of CTC, CTC-2 beginning on day 28 after the first APCT. One patient died of sepsis, one developed reversible veno-occlusive disease (VOD). Eleven patients received 3 subsequent courses of CTC. There were three toxic deaths: 1 × sepsis, 1 × VOD, 1 × hemolytic uremic syndrome (HUS). Two other patients developed reversible VOD, one had reversible HUS. While two closely spaced CTC courses are feasible, three subsequent courses are associated with frequent unacceptable organ toxicity. Preliminary data of a phase I/II study in advanced breast cancer suggest that three tightly spaced ‘tiny CTC’ courses—containing 2/3 of the doses of each of the agents in a standard CTC course—may be well tolerated and are not associated with excess organ toxicity." @default.
• W2061821116 created "2016-06-24" @default.
• W2061821116 creator A5021960841 @default.
• W2061821116 creator A5040015584 @default.
• W2061821116 creator A5063335991 @default.
• W2061821116 creator A5082601500 @default.
• W2061821116 creator A5090670668 @default.
• W2061821116 creator A5090786009 @default.
• W2061821116 date "1995-11-01" @default.
• W2061821116 modified "2023-10-02" @default.
• W2061821116 title "12 Multiple courses of high-dose alkylating therapy with autologous stem cell support" @default.
• W2061821116 doi "https://doi.org/10.1016/0959-8049(95)95264-7" @default.
• W2061821116 hasPublicationYear "1995" @default.
• W2061821116 type Work @default.
• W2061821116 sameAs 2061821116 @default.
• W2061821116 citedByCount "0" @default.
• W2061821116 crossrefType "journal-article" @default.
• W2061821116 hasAuthorship W2061821116A5021960841 @default.
• W2061821116 hasAuthorship W2061821116A5040015584 @default.
• W2061821116 hasAuthorship W2061821116A5063335991 @default.
• W2061821116 hasAuthorship W2061821116A5082601500 @default.
• W2061821116 hasAuthorship W2061821116A5090670668 @default.
• W2061821116 hasAuthorship W2061821116A5090786009 @default.
• W2061821116 hasConcept C126322002 @default.
• W2061821116 hasConcept C126894567 @default.
• W2061821116 hasConcept C141071460 @default.
• W2061821116 hasConcept C201750760 @default.
• W2061821116 hasConcept C2776694085 @default.
• W2061821116 hasConcept C2776755627 @default.
• W2061821116 hasConcept C2778239845 @default.
• W2061821116 hasConcept C2778384902 @default.
• W2061821116 hasConcept C2779968505 @default.
• W2061821116 hasConcept C2780007613 @default.
• W2061821116 hasConcept C2781413609 @default.
• W2061821116 hasConcept C2781451048 @default.
• W2061821116 hasConcept C28328180 @default.
• W2061821116 hasConcept C54355233 @default.
• W2061821116 hasConcept C71924100 @default.
• W2061821116 hasConcept C86803240 @default.
• W2061821116 hasConcept C90924648 @default.
• W2061821116 hasConceptScore W2061821116C126322002 @default.
• W2061821116 hasConceptScore W2061821116C126894567 @default.
• W2061821116 hasConceptScore W2061821116C141071460 @default.
• W2061821116 hasConceptScore W2061821116C201750760 @default.
• W2061821116 hasConceptScore W2061821116C2776694085 @default.
• W2061821116 hasConceptScore W2061821116C2776755627 @default.
• W2061821116 hasConceptScore W2061821116C2778239845 @default.
• W2061821116 hasConceptScore W2061821116C2778384902 @default.
• W2061821116 hasConceptScore W2061821116C2779968505 @default.
• W2061821116 hasConceptScore W2061821116C2780007613 @default.
• W2061821116 hasConceptScore W2061821116C2781413609 @default.
• W2061821116 hasConceptScore W2061821116C2781451048 @default.
• W2061821116 hasConceptScore W2061821116C28328180 @default.
• W2061821116 hasConceptScore W2061821116C54355233 @default.
• W2061821116 hasConceptScore W2061821116C71924100 @default.
• W2061821116 hasConceptScore W2061821116C86803240 @default.
• W2061821116 hasConceptScore W2061821116C90924648 @default.
• W2061821116 hasLocation W20618211161 @default.
• W2061821116 hasOpenAccess W2061821116 @default.
• W2061821116 hasPrimaryLocation W20618211161 @default.
• W2061821116 hasRelatedWork W1973702706 @default.
• W2061821116 hasRelatedWork W2000611656 @default.
• W2061821116 hasRelatedWork W2030259539 @default.
• W2061821116 hasRelatedWork W2036215475 @default.
• W2061821116 hasRelatedWork W2318280718 @default.
• W2061821116 hasRelatedWork W2327014840 @default.
• W2061821116 hasRelatedWork W2390233036 @default.
• W2061821116 hasRelatedWork W2403217642 @default.
• W2061821116 hasRelatedWork W2416746630 @default.
• W2061821116 hasRelatedWork W434627019 @default.
• W2061821116 hasVolume "31" @default.
• W2061821116 isParatext "false" @default.
• W2061821116 isRetracted "false" @default.
• W2061821116 magId "2061821116" @default.
• W2061821116 workType "article" @default.